openaccess.sgul.ac.ukopenaccess.sgul.ac.uk/107658/...lancetid_accepted.docx · web viewwho...
TRANSCRIPT
HIV-exposed uninfected infants: new global challenges in the era of paediatric
HIV elimination
Ceri Evans1,2, Christine E Jones3, Andrew J Prendergast1,2,4
1Blizard Institute, Queen Mary University of London, London, UK
2Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe
3Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity,
St George’s, University of London, London, UK
4Department of International Health, Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, USA
Corresponding author: Dr Andrew J Prendergast, Centre for Genomics and Child
Health, Blizard Institute, Queen Mary University of London, 4 Newark Street,
London, E1 2AT, UK
Tel: +44 207 882 2269
Fax +44 207 882 2195
Short title: HIV-exposed uninfected infants
Word count: 4997
Abstract: 152
References: 160
Key words: HIV, infant, Africa, immune activation, mortality, infections, growth
1
ABSTRACT
With scale-up of interventions to achieve elimination of paediatric HIV infection, the
number of HIV-infected infants is declining, but the number of uninfected infants
exposed to maternal HIV is increasing. Interest in the health outcomes of HIV-
exposed uninfected (HEU) infants has grown over the last decade, with several
studies suggesting increased mortality, infectious morbidity and growth failure
compared to HIV-unexposed infants. However, heterogeneous results may reflect the
inherent challenges in studies of HEU infants, which require large populations with
appropriate, contemporaneous comparison groups and repeat HIV testing throughout
the period of breastfeeding. Here we review the effects of HIV exposure on mortality,
morbidity and growth, discuss the immunological abnormalities so far identified, and
provide an overview of interventions that may be effective in this vulnerable
population. As the number of HIV-infected infants declines, the health needs of HEU
infants should be prioritised further, to ensure that post-2015 Sustainable
Development Goals are achieved.
2
INTRODUCTION
Mother-to-child transmission is one of the great tragedies of the HIV epidemic,
particularly in sub-Saharan Africa, where 90% of new infections occur. Although the
global target to eliminate paediatric HIV by 2015 has not been attained, there has
been huge progress in reducing the number of HIV-infected infants through scale-up
of prevention of mother-to-child transmission (PMTCT) programmes. In the pre-
antiretroviral therapy (ART) era, up to 40% of infants acquired HIV from their
mothers,1 but with increasing availability of effective PMTCT interventions,
transmission rates close to 1% are possible among breastfeeding populations in
developing countries,2 and <1% among non-breastfeeding populations.3 The current
public health approach to PMTCT is initiation of lifelong ART for all pregnant and
breastfeeding women (so-called Option B+)4 to eliminate new HIV infections among
children and keep their mothers alive.5 As PMTCT coverage expands, therefore, the
number of HIV-infected infants is declining, but the number of HIV-exposed
uninfected (HEU) infants is increasing (Figure 1). As progress towards elimination of
paediatric HIV infection accelerates, a potentially vulnerable population of HEU
infants, with uncertain health needs, is growing. In this Review, we summarise the
evidence regarding mortality, infectious morbidity, immune function and growth of
HEU infants, and highlight research gaps that need addressing to better define
interventions for this growing population.
3
MORTALITY AND MORBIDITY
The observation that infants exposed to HIV, but not infected, might have increased susceptibility
to infections first emerged in 1992 when HEU infants in Kenya were found to have a high
incidence of measles.6 In 1993, HEU infants in Zaire were noted to have a greater risk of persistent
diarrhoea than HIV-unexposed infants;7 HEU infants were highlighted as a priority group, as few
management options were available for HIV-infected infants at that time. However, despite many
subsequent studies, the precise impact of vertical HIV exposure on child health outcomes remains
unclear. Interpretation of published findings is complicated by several factors: first, early studies
lacked HIV testing, making the impact of HIV exposure difficult to separate from infant HIV
infection; second, follow-up testing of HIV-uninfected mothers and infants to ensure accurate HIV
status is often lacking; third, HIV-unexposed comparison groups have either not been included, or
are not demographically comparable; fourth, HEU and HIV-unexposed infants often differ in
breastfeeding uptake and/or duration; and fifth, contemporary studies cannot distinguish the
relative contributions of HIV and ART exposure. Despite these limitations, several large studies
suggest that HEU infants have increased mortality and morbidity in early life.
Mortality in the pre-ART era
The largest HEU cohort (ZVITAMBO), which prospectively followed 14110 infants in Zimbabwe
prior to availability of ART, found 3-fold higher mortality among HIV-exposed compared to HIV-
unexposed infants through 2 years of follow-up; this mortality risk was higher in the first
compared to the second year of life (Table 1). Infants and mothers had regular HIV testing, and
sensitivity analyses showed that elevated mortality was not due to unascertained postnatal HIV
transmission.8 A study from Uganda reported significantly higher mortality among HEU infants at
18 months of age, but not at 12 or 24 months.9 A Zambian study, which prospectively assessed
infants from 9 months to 3 years of age, demonstrated 3-fold higher mortality in HEU compared to
HIV-unexposed children (95%CI 0·7-14·0).10 Statistical power in these latter studies may have
4
been limited by relatively small sample sizes. Studies with longer follow-up report mixed results.
HEU children in Rwanda had no increase in mortality through 5 years,11 but in The Gambia, HIV-
1- and HIV-2-exposed uninfected children surviving beyond 4 months of age had increased
mortality through median 6 years compared to HIV-unexposed children.12
Mortality in the ART era
Where infants were exposed to limited PMTCT (single-dose nevirapine/zidovudine monotherapy),
results have been heterogeneous. A large South African study showed no difference in 12-month
mortality between HEU and HIV-unexposed groups; the majority of infants in both groups were
exclusively breastfed, which may have partially mitigated differences.13 A smaller South African
study, where HEU infants were less likely than HIV-unexposed infants to breastfeed beyond 12
weeks, showed no difference in mortality through 36 weeks,14 although approximately one-third
were recruited from a wealthier area where formula feeding may have been safe. HEU infants
exposed to single-dose nevirapine and 6 months of zidovudine for PMTCT in the Mashi trial in
Botswana had 4-fold higher mortality than HIV-unexposed infants through 24 months.15 In a large
trial in Malawi, Tanzania and Zambia, HEU infants had 50% higher 12-month mortality despite
single-dose nevirapine and co-trimoxazole prophylaxis.16A small study from Mozambique, in
which HIV-exposed infants received co-trimoxazole prophylaxis, single-dose nevirapine and 4
weeks of zidovudine, found a trend towards increased mortality in HEU infants (OR 3·74, 95%CI
0·41-34·3).17 In a small Ugandan study, HEU infants exposed to PMTCT and receiving co-
trimoxazole prophylaxis had almost 14-fold increased mortality (OR 13·7, 95%CI 1·12-167·3),
but breastfeeding duration was significantly shorter than for HIV-unexposed infants.18
Studies comparing mortality in middle- and high-income-countries are lacking, but there is a need
to determine the impact of HIV exposure in these settings, particularly in the current ART era.
5
All-cause morbidity and hospitalisation
Prior to the availability of ART, HEU infants in the ZVITAMBO trial had more hospitalisations
during the neonatal period and more all-cause sick clinic visits throughout infancy, compared to
HIV-unexposed infants, particularly for pneumonia and oral thrush.19 In the ART era, a large
South African study found no difference in late-onset sepsis, and a slightly lower incidence of
early-onset sepsis, in HEU infants during the neonatal period. However, HEU infants receiving
single-dose nevirapine and 6 months of zidovudine for PMTCT in the Mashi trial in Botswana had
over 2-fold higher hospitalisation compared to HIV-unexposed infants through 24 months.15
Among infants surviving to 20 months of age in Malawi, there were no differences in
hospitalisation between HEU and HIV-unexposed infants, although this study may have been
limited by survival bias.20 One small study from South Africa showed that, while the frequency of
infections in HEU and HIV-unexposed infants was similar, HEU infants had a trend towards more
hospitalisations (RR 2·74, 95%CI 0·85-8·78).21 HEU infants in Mozambique receiving co-
trimoxazole prophylaxis, single-dose nevirapine and 4 weeks of zidovudine, had fewer outpatient
clinic attendances than HIV-unexposed infants at 12 months, and similar hospitalisation rates.17
The most common infections in HEU infants are skin infections, lower respiratory tract infections
and oral thrush, in sub-Saharan Africa,19 Latin America and the Caribbean.22 There are reports of
unusual infections in HEU infants, including invasive group A streptococcal disease, haemorrhagic
varicella and recurrent oral candida. HEU infants also appear to have more severe infections and a
greater risk of treatment failure, especially for pneumonia,21,23-26 and higher rates of surgical
complications.27
Pneumonia
Pneumonia was more common in HEU infants through 6 months of age in Zimbabwe; in
sensitivity analyses including only those surviving to the end of the interval, HEU infants had over
6
3-fold more hospitalisations for pneumonia during the neonatal period (OR 3.4, 95%CI 1.9-6.0).19
HEU infants in South Africa had increased incidence of invasive pneumococcal disease compared
to HIV-unexposed infants, before and after introduction of pneumococcal conjugate vaccine.28,29
Several studies have described pneumonia caused by an unusually broad range of organisms in
HEU infants, including Staphylococcus aureus; 24 E. coli; Pseudomonas aeruginosa and other
Gram-negative bacteria;24,30 cytomegalovirus and other viruses;24,30,31 and Pneumocystis
jirovecii.24,25,32-36 Differences in outcome may therefore be partly due to a different spectrum of
causative organisms, which are not treated by standard first-line antimicrobial regimens, or altered
pathogen-specific immune responses.
Tuberculosis
HEU infants in developing countries may be at greater risk of tuberculosis (TB). In a South
African series, four of eight infants with congenital TB were HEU infants; a further two were
HIV-exposed but did not undergo virological testing.37 Compared to HIV-unexposed infants in
Uganda, HEU infants had a 2·6-fold increased odds of TB infection, diagnosed by tuberculin skin
testing or interferon-gamma release assay.38
Diarrhoea
Studies from sub-Saharan Africa comparing the incidence of diarrhoea between HEU and HIV-
unexposed infants may partly be confounded by feeding practices, due to changes over time in
breastfeeding recommendations for HIV-infected mothers. A comparison between formula-fed
HEU infants and breastfed HIV-unexposed infants in Uganda demonstrated a 6-fold higher risk of
severe diarrhoea in HEU infants at 6-11 months of age,18 whilst in Mozambique, HEU infants had
less diarrhoea and a similar frequency of diarrhoea-related hospitalisation as HIV-unexposed
infants, despite a shorter duration of breastfeeding.17 Other studies not reporting breastfeeding rates
had mixed results, with some showing a higher frequency of diarrhoea23 or persistent diarrhoea,24
7
and others showing no differences.24,30 After adjusting for feeding practices in South Africa, there
were no significant associations between HIV exposure and acute, persistent or overall diarrhoea
to 6 months of age,13 and in the ZVITAMBO trial, where almost all HEU infants were breastfed,
HEU infants did not have more acute diarrhoea than HIV-unexposed infants.19
Morbidity in developed countries
Fewer studies have assessed morbidity among HEU infants in developed countries, where routine
ART exposure, lower background infectious morbidity and a lack of appropriate HIV-unexposed
control groups from similar socioeconomic backgrounds make the impact of HIV exposure harder
to determine. Despite these limitations, several studies suggest elevated infectious morbidity
among HEU infants. In a French study of 7638 HEU infants, a high proportion (9·3%) required
hospitalisation for serious infections during the first year of life;39 however, no HIV-unexposed
control group was assessed and there was potential for hospitalisation bias. The most common
bacterial infection was pneumonia caused by encapsulated organisms (Streptococcus pneumoniae
and Haemophilus influenzae); the risk was inversely associated with maternal CD4 count for
serious bacterial, but not viral, infections. In a Belgian cohort, HEU infants had almost 20-fold
increased incidence of invasive group B streptococcal disease compared to unexposed infants in
the first month of life (RR 19·6, 95%CI 7·5-51·7), although the absolute number of cases was
small.40 HEU infants remained at risk of infection over the first year of life, with a 13-fold
increased odds of invasive group B streptococcal disease and 4-fold increased odds of invasive
pneumococcal disease compared to HIV-unexposed infants.41 HEU infants born in the ART era
had almost 3-fold higher morbidity that those born prior to ART availability (adjusted HR 2·93,
95%CI 1·07-8·05), whether or not mothers actually received ART. A Danish study reported
increased hospitalisation among HEU compared to HIV-unexposed children over the first four
years of life; however, this increase was related to haematological disorders rather than infectious
diseases.42
8
Opportunistic infections
Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection of HIV-infected infants, but
was reported in two 7-week-old HEU infants from Texas in 1997;32 in each case, infection was
associated with a transient drop in CD4 count. Further cases of PCP pneumonia in HEU infants
below 6 months of age have been reported from France,39 South Africa24,25,43 and the USA.36 In
South Africa, over half of children admitted to hospital with acute hypoxic pneumonia had PCP
detected using molecular techniques; HIV exposure and malnutrition were risk factors among
HIV-uninfected children.13 Infants in this study were thoroughly investigated, meaning the burden
of PCP in HEU infants elsewhere may be higher than previously recognised.
Causes of excess mortality and morbidity
Despite heterogeneity in the literature, the body of evidence from multiple settings indicates
increased morbidity and mortality among HEU infants, and a risk of severe, unusual and
complicated infections, compared to HIV-unexposed infants. The causes of excess morbidity and
mortality are likely multifactorial, and may be partly driven by adverse environmental and socio-
economic conditions. However, morbidity and mortality differences remain after adjustment for
socio-economic status,8,19,44 and findings are not driven purely by differences in maternal care-
taking capacity due to ill health;44,45 duration of breastfeeding45 and quality of breast milk;15 or
colonisation46 or vertical transmission47 of pathogens. Several studies report associations between
HEU infant mortality and maternal HIV disease severity, assessed either by maternal CD4
count,8,44,45,48-50 viral load44,48,49,51 or mortality44,45,48-50 (Supplementary Table 1). Incidence of
respiratory tract infection has also been associated with severity of maternal HIV disease in several
studies.19,22,52,53 In Zimbabwe, increased infectious morbidity remained even at maternal CD4
counts >500 cells/uL, and only disappeared with CD4 >800 cells/uL.19 HEU infants have evidence
of immunological abnormalities that may at least partly explain their poor health outcomes.
9
IMMUNE DYSFUNCTION
A recent review provides an excellent overview of the immunology of HEU infants.54 Here, we
summarise the likely causes of immune dysfunction in HEU infants and discuss additional recent
studies.
Immune activation
Chronic immune activation is the hallmark of HIV infection, and is driven by multiple factors,
including HIV itself, chronic co-infections, and intestinal microbial translocation.55 HEU infants
are therefore born to mothers who have high levels of pro-inflammatory cytokines and activated T-
and B-cells during pregnancy.56 There is similarly evidence of immune activation in both innate
and adaptive immune cells of HEU infants compared to HIV-unexposed controls. In a recent study
of Zimbabwean infants, a more pro-inflammatory milieu (indicated by raised C-reactive protein)
was evident in HEU, compared to HIV-unexposed, infants at 6 weeks of age, and was still evident
at 6 months of age.57 HEU infants born to ART-treated women with undetectable viral loads had
significantly higher concentrations of pro-inflammatory cytokines (IL-1β and IL-8) than HIV-
unexposed controls.58 In HEU compared to HIV-unexposed infants, stimulated monocytes and
dendritic cells secrete higher concentrations of pro-inflammatory cytokines,59 dendritic cells have
greater up-regulation of the activation markers CD80 and CD86,60 and natural killer (NK) cells
have higher expression of the activation markers CD38(bright) and CD69.61 T-cells show a shift
towards memory (CD45RA-) and away from naïve (CD45RA+) phenotypes,62,63 have higher
expression of the activation markers CD154 and CD38,63-66 and demonstrate greater proliferation
but reduced polyfunctionality (i.e. produce fewer different cytokines) upon stimulation.67
Compared to HIV-unexposed controls, CD4 T-cells show higher expression of inflammatory
response-related chemokine receptors (in particular CCR3 and CCR8), and in vitro stimulation
results in up-regulation of CCR8 expression and TNF-α.58,68 These findings suggest an immune-
10
priming role of HIV exposure; activated cells are more susceptible to HIV infection in vitro, and
potentially other intracellular infections.58
T-cell number and function
HEU infants have lower absolute numbers of CD4 T-cells, which may be due to more apoptosis;69
HEU infants at 10 weeks of age in Malawi had similar CD4 counts to HIV-infected infants.62 In
Mozambique, the CD4 percentage was 3% lower, and CD8 percentage 1·15-fold higher in HEU
compared to HIV-unexposed infants in multivariate longitudinal analysis.17 Thymic dysfunction70
may account for high levels of circulating ‘double negative’ (CD4-/CD8-) T-cells in HEU
infants.65 HEU infants have evidence of HIV-specific T-cell responses,71 even in the context of
maternal ART, suggesting that exposure to HIV antigens occurs in utero.
Humoral immunity and vaccine responses
At birth, HEU infants in developing and developed countries have lower concentrations of specific
antibody to vaccine-preventable infections compared to HIV-unexposed infants.72-76 Lower
concentrations of specific antibodies in HIV-infected mothers, compounded by reduced
transplacental transfer of antibody from mother to infant, appears to account for the paucity of
antibody in newborn HEU infants,73,74,77-80 although there is no association between maternal CD4
count or viral load and transplacental transfer of antibody.73
However, responses to primary vaccination in HEU infants are similar (for diphtheria, tetanus,
Haemophilus influenzae B, and BCG),68,73,76,81-83 or even increased (for pertussis, pneumococcal
capsular polysaccharide and measles),73,75,76,81,84,85 compared to HIV-unexposed infants (Table 2;
Supplementary Table 2), and HEU infants have good serological evidence of protection following
combined measles, mumps and rubella (MMR) vaccination.86 Furthermore, the fold-increase of
antibody concentration from pre- to post-vaccination is higher among HEU infants compared to
11
HIV-unexposed infants.73 An explanation for this is reduced interference of maternally acquired
antibody on infant B-cell response to vaccination, which has been reported for multiple vaccines.
Although the mechanism in humans is unknown, in animal models this appears to be due to cross-
linking of the B-cell receptor with the regulatory receptor FcγRIIB.87 Where the concentration of
pre-vaccination antibody is increased in HEU compared to HIV-unexposed infants, lower
concentrations are observed post-immunisation.76,85 The functionality of vaccine-specific antibody
is similar in HEU and unexposed infants.72,79 These factors support the hypothesis that differences
in vaccine responses are driven by the concentration of maternally derived antibody pre-
vaccination, rather than differences in infant B-cell function.
BIRTH, GROWTH AND DEVELOPMENT
Long-term nutritional and neurodevelopmental outcomes are influenced by environmental factors
during the first thousand days – the period from conception to 2 years of age
(www.thousanddays.org). HIV exposure during this period may therefore critically impact birth,
growth and development. In developing countries, HEU newborns may be more likely to be small
for gestational age (SGA) or low birth weight (LBW) compared to HIV-unexposed newborns
(Table 3; Supplementary Table 3). LBW among HEU infants is associated with 2·5-12-fold
increased mortality,45,49,88,89 particularly due to pneumonia.53 In HEU infants, preterm birth, LBW,
and SGA were each associated with at least 6-fold increased neonatal mortality, and at least 2-fold
increased mortality up to 1 year of age.51
Data on postnatal growth in HEU infants is heterogeneous (Supplementary Table 3). Before the
availability of ART (Table 3), the largest study (ZVITAMBO) showed that HEU infants had more
stunting, wasting and underweight than HIV-unexposed infants throughout infancy.90 Length-for-
age remained lower through 24 months of age in Zimbabwe90 and Malawi91 (Table 3). Stunting
(linear growth failure) has been associated with maternal disease severity in some92,93 but not all90
12
studies. Impaired growth in HEU infants was not seen in several, mostly smaller, studies, although
many showed non-significant trends towards poorer growth (Supplementary Table 3). A large
study from South Africa, where nevirapine was used for PMTCT and most infants were
exclusively breastfed, did not find a difference in weight-for-age Z-scores over the first 24
months.94 In Zambia, breastfed compared to formula-fed HEU infants had better weight-for-age,
but not length-for-age, Z-scores to 15 months of age.95 Large, well-designed studies in the context
of fully suppressive maternal ART are required to determine the effect on growth in the current
era.
There is emerging interest in the impact of impoverished environments on poor linear growth, so
the cleaner environments of developed countries may mitigate growth concerns. However, results
have been heterogeneous. HEU infants in the UK had normal length and weight compared to HIV-
unexposed controls at 3 years.96 Compared to formula-fed HIV-unexposed controls, formula-fed
HEU infants in Italy had similar weight-for-length and weight-for-age Z-scores, but poorer length-
for-age Z-scores at 18 and 24 months of age.97 In the USA, ART-exposed HEU newborns had
lower weight and length at birth than matched HIV-unexposed controls, but growth accelerated
during infancy, such that anthropometric measurements were similar by 10 months.98
The impact of HIV exposure on neurodevelopment remains uncertain. A systematic review from
2012 identified mostly studies with methodological shortcomings from high-income settings
without control groups.99 The authors concluded that, once confounders were accounted for (in
particular, maternal substance misuse), there was unlikely to be developmental delay up to 2 years
of age in HEU infants. More recent studies from Malawi20 and Colombia100 reported no significant
developmental differences at 20 and 24 months of age, respectively. Six- to eight-year-old
Zimbabwean children did not have more cognitive impairment than HIV-unexposed controls (OR
1·32, 95%CI 0·69-2·52).101 However, HEU Zambian children showed poorer mathematics, but not
13
English, grades at 6-12 years of age than HIV-unexposed children after adjusting for
socioeconomic status.102 After adjusting for plausible confounders, including carer education, HEU
children aged 2-12 years in Thailand had poorer verbal IQ, full-scale IQ and Binet-Bead Memory
scores compared to HIV-unexposed controls, although differences were small and their clinical
significance remains questionable.103 A Thai study comparing HEU with HIV-unexposed children
at a mean age of 10·3 years, showed no difference in neuroanatomy or brain integrity measured by
magnetic resonance imaging with diffusion tensor imaging, after adjusting for socioeconomic
status.104
MECHANISMS UNDERLYING ADVERSE OUTCOMES IN HEU INFANTS
Multiple factors may contribute to the excess risk of morbidity, mortality and growth failure that
has been reported for HEU infants.
Family environment
There is a high risk of orphanhood in HIV-affected households; over 17 million children are
estimated to have lost at least one parent to AIDS since the beginning of the HIV epidemic.105 For
each woman dying of AIDS in Africa, an average of two children are orphaned.106 Maternal
mortality is associated with poor infant outcomes regardless of the cause of death,107 because
mothers who are sick may have impaired capacity to care for their offspring, and orphaned
children are subject to extreme poverty and homelessness.108 However, the death of a mother with
advanced HIV may exacerbate immune abnormalities in her offspring, compounding the morbidity
risk in HEU infants109 (see below). Even among mothers who survive, HIV infection has far-
reaching consequences for families. HIV-infected parents are at risk of poverty because of
inability to work, which may affect food security and access to healthcare for the household. HEU
children may adopt caregiver roles for infected family members, or may be neglected when other
14
children in the family are HIV-infected. Furthermore, HEU infants may be brought up in an
environment with greater exposure to pathogens, including tuberculosis.110
Immune activation
Immune activation and systemic inflammation may lead to infection susceptibility and growth
failure. Each may be explained by in utero and postnatal exposure to HIV. Immune activation may
result from exposure to a pro-inflammatory fetal environment or from exposure to coinfections
(such as CMV111) or HIV itself; HEU infants have evidence of HIV-specific T-cell responses,71
suggestive of in utero HIV exposure.112 Maternal bacterial translocation, which causes immune
activation in HIV infection,56 may directly affect the developing immune system during fetal life,
although further studies are needed to explore this hypothesis. Postnatal exposure to HIV through
breastfeeding may disrupt the intestinal mucosal barrier; in vitro experiments found impaired tight
junction function within 2-4 hours of intestinal epithelial cell exposure to HIV, and this
dysfunction was associated with bacterial translocation.113
Antiretroviral therapy
Prolonged exposure to ART during the developmentally sensitive period from conception to the
end of breastfeeding could be associated with risks. A detailed discussion of these issues is beyond
the scope of this Review, but ART may be associated with preterm birth114 and mitochondrial
toxicity115. Associations between ART and congenital abnormalities are reported in some
studies116,117 but not others.118,119 Although an association was shown between antenatal tenofovir
and postnatal growth failure in one US study, similar results have not been reported from sub-
Saharan Africa.119 A recent analysis from Botswana showed that HEU children exposed to
maternal combination ART had significantly lower length-for-age and weight-for-age Z-scores at
24 months than those exposed to zidovudine monotherapy.120
15
INTERVENTIONS FOR HEU INFANTS
HEU infants are a vulnerable population who may benefit from additional monitoring and
interventions. Here we review the evidence behind existing interventions and consider the
potential benefits of additional management approaches.
Antiretroviral therapy
Since lifelong ART for pregnant and breastfeeding women is an essential component of the efforts
to eliminate paediatric HIV infection, the benefits outweigh currently reported risks of antenatal
ART exposure. Few studies have compared health outcomes of HEU infants exposed or
unexposed to maternal ART, although one study reported an 81% reduction in mortality to 10
years of age (aHR 0·19, 95%CI 0·06-0·59) among infants exposed to maternal ART and receiving
co-trimoxazole, compared to those without interventions.121 With expansion of PMTCT Option
B+, more women will conceive on ART, and maternal virological suppression and CD4
reconstitution before pregnancy should have positive impacts on the health of HEU infants.
Longitudinal studies of well-characterised cohorts in sub-Saharan Africa are required to determine
whether maternal ART normalises immune function, growth and health in HEU infants, or
whether additional interventions are required.
Co-infections
Whether HEU infants would benefit from additional interventions to reduce PCP, TB and vaccine-
preventable infections is unclear. WHO recommends co-trimoxazole prophylaxis for all HEU
infants from 4-6 weeks of age until cessation of breastfeeding,122 because of the ongoing risk of
HIV transmission and rapid disease progression among infected infants. Although side-effects
have been noted17 co-trimoxazole is generally well tolerated in HEU infants, and safety data for
antenatal123 and postnatal124 co-trimoxazole support its use as a universal intervention. In a study
from Mozambique, HEU infants receiving co-trimoxazole had fewer clinic attendances than HIV-
16
unexposed infants not receiving co-trimoxazole (incidence ratio 0·79, 95%CI 0·63-0·99),17
although in trial data from Malawi, Zambia and Tanzania, HEU infants receiving co-trimoxazole
had 12-month mortality of 7·2% compared to 4·8% among HIV-unexposed infants.16 In a non-
randomised comparison of infants in the Malawian BAN trial, co-trimoxazole was associated with
short-term protection from malaria, but had no impact on a combined endpoint of severe illness or
death through 36 weeks of age.125 However, subsequent analysis found that co-trimoxazole was
associated with reductions in pneumonia, serious febrile illness, diarrhoea, growth faltering and
malaria throughout the first year of life.89 Although protection from malaria is commonly
reported,89,125-127 not all studies have shown reductions in diarrhoea and pneumonia among HEU
infants receiving co-trimoxazole, and it has been argued that the risks of co-trimoxazole may
outweigh benefits.128 To address this uncertainty, two randomised trials of co-trimoxazole in HEU
infants are currently underway in Botswana (ClinicalTrials.gov identifier NCT01229761) and
South Africa (Pan-African Clinical Trials Registry identifier PACTR201311000621110).
Interventions to prevent TB have been unsuccessful; isoniazid preventive therapy did not reduce
TB infection among HEU infants in South Africa.129
Vaccinations
Vaccine responses appear broadly similar in HEU and HIV-unexposed infants, highlighting the
importance of timely and complete vaccination. However, there remains a paucity of clinical data
on vaccine effectiveness in this group.130 Vaccine strategies which may mitigate the risk of
infectious morbidity early in life include antenatal immunisation, neonatal vaccination and earlier
commencement of vaccine schedules. However, antenatal vaccination in the context of HIV may
be associated with reduced maternal immunogenicity and therefore reduced transplacental transfer
of antibody to the infant,131 especially in increased maternal disease severity.132 Earlier infant
vaccination may be more efficacious, although the feasibility of delivering such a programme in
developing countries has not been evaluated, and is likely to be a major barrier. In HIV-prevalent
17
settings, BCG should be delayed until infant HIV status has been confirmed to avoid vaccinating
HIV-infected infants, who are at risk of disseminated BCG disease.133
Infant feeding
Early cessation of breastfeeding reduces HIV transmission but increases morbidity and mortality
from other causes in developing countries.13,49,134-139 In Zambia, shortening the duration of
breastfeeding increased infant mortality,44 even if weaning occurred in the second year of life.49 In
Uganda, mortality was 6·2-fold higher in HEU infants breastfed for fewer than 6 months
compared to those breastfed for longer (95%CI 1·4-27·0).137 A Malawian trial found an association
between breastfeeding cessation and mortality and morbidity among HEU infants from 6-15
months of age.138 Most140-142 but not all50 studies comparing breastfeeding with replacement feeding
from birth report increased morbidity or mortality in formula-fed infants. Compared to breastfed
HEU infants, formula-fed HEU infants in South Africa had twice the frequency of illness in the
first two months of life (OR 2·02, 95%CI 1·16-3·51).141 In a trial from Burkina Faso, Kenya and
South Africa, HEU infants who were formula-fed from birth had 6-fold more serious infections
than those who were breastfed (adjusted OR 6·0, 95%CI 2·2-16·4).142 After adjusting for infant
growth and maternal disease status, breastfeeding among HEU infants in Kenya was associated
with 47% lower risk of pneumonia compared to never breastfeeding (HR 0·53, 95%CI 0·39-
0·73).140 However, causative organisms among HEU infants with diarrhoea or pneumonia did not
differ by feeding strategy in a recent analysis from the Mashi trial in Botswana.30
Although replacement feeding is recommended within PMTCT programmes in developed
countries, it is only recommended in developing countries if it is acceptable, feasible, affordable,
sustainable and safe.143 Breast milk of HIV-infected women has similar levels of innate immune
factors and specific immunoglobulins as HIV-uninfected women.15,144 Breastfeeding in the context
of Option B+, where women are on lifelong ART, leads to low levels of HIV transmission.
18
CONCLUSIONS
As progress is made towards elimination of paediatric HIV infection, there is a growing interest in
the health needs of HEU infants. The population remains challenging to study because of the
confounding effects of ART exposure and feeding modality, difficulties in confirming HIV status
and lack of comparable, contemporaneous control groups. However, the largest study, which
followed over 3000 well-characterised HEU infants before availability of ART in Zimbabwe,
demonstrated increased mortality,8 infectious morbidity19 and growth failure,90 in line with several
other well-designed, but smaller, studies.9,15,16,28,29,91,145,146 A South African study undertaken in the
pre-ART era with high exclusive breastfeeding rates found no differences in mortality13 or
growth94 of HEU and HIV-unexposed infants, meaning uptake of exclusive breastfeeding may at
least partly mitigate adverse outcomes.
Reports from developed countries suggest that, despite maternal ART, HEU infants remain at
increased risk of infections.39-41 Immunological abnormalities have been reported in HEU infants
from both developing and developed countries. These may persist despite maternal ART, although
prospective studies of appropriate cohorts are needed to determine the relative importance of
immune function, feeding practices and family environment in mediating poor outcomes of HEU
infants (Panel 1). Further detailed immunological analyses using modern laboratory techniques are
required, particularly in well-characterised cohorts from sub-Saharan Africa. Reassuringly, HEU
infants mount robust responses to vaccination; timely vaccination is vital to reduce the risk of
vaccine-preventable infections. HEU infants should remain in clinical follow-up after early infant
diagnosis at 4-6 weeks of age, with repeat HIV testing after complete cessation of breastfeeding.
Although breastfeeding increases the risk of HIV acquisition, transmission rates in the context of
fully suppressive maternal ART are low (approximately 0·2% per month147) and prolonged
breastfeeding reduces mortality in settings where formula feeding is unsafe.
19
Prevention of mother-to-child transmission of HIV is an evolving success story, although several
challenges remain in the quest to eliminate paediatric HIV. Integration of PMTCT into broader
maternal, newborn and child health services would fulfil the objective of improving child and
maternal survival together.148 However, as the number of HIV-infected infants declines, the health
needs of HEU infants should be prioritised further, to ensure that post-2015 Sustainable
Development Goals are achieved.
20
Search strategy and selection criteria
We searched PubMed using the terms (HIV or human immunodeficiency virus[MeSH Terms]) AND
(expos* or uninfected or maternal or affect*[MeSH Terms]) AND (child* or infant* or fetus or fetal or
foet* or neonat*[MeSH Terms]) for English language papers from January 1983- November 2015. We
reviewed citation lists of included studies and screened abstracts from relevant conference proceedings.
Articles were selected if infants were diagnosed as HIV-exposed uninfected. A systematic review was
beyond the scope of this article. Larger, better quality, and more recent studies with contemporaneous
comparison groups were preferentially selected, as were systematic reviews/meta-analyses of previous
data. Studies were preferentially included if direct comparisons between HIV-exposed and HIV-
unexposed groups were used. Studies were excluded if the HIV status of infants was not established
with virological testing.
21
TABLESTable 1: Studies comparing mortality in HEU and HIV-unexposed infantsCountry
N (HEU)
N (HUU)
HIV testing Feeding Outcome Result Comments
Pre-ART
Zimbabwe8
3135
9510
Mothers and infants tested at each visit
EBF at 3mo:HEU 10.5% vs. HUU 9.3% (NS)
Predominant BF at 3mo:HEU 30.6% vs. HUU 31.9% (NS)
Mixed BF at 3mo:HEU 58.9% vs. 58.9% (NS)
12mo mortality aHR 3.9 (95%CI 3.15-4.78)(aHR 2.5 on sensitivity analysis)
Very large number of HEU and HIV-unexposed infants Comparable, contemporaneous and demographically similar comparison group Most infants in both groups did not exclusively breastfeed Regular HIV testing undertaken Sensitivity analysis supported primary findings
24mo mortality aHR 2.0 (95%CI 1.2-3.5)(aHR 2.0 on sensitivity analysis)
Uganda9
269
3183
Infants tested several times; mothers not re-tested
98% breastfed
Duration/exclusivity not reported
12mo mortality RR 1.08 (NS) Small number of HEU infants Infants rested regularly – HEU group unlikely to be contaminated with postnatally infected infants Mothers not retested – unexposed group possibly contaminated with HEU or HIV-infected infants
18mo mortality RR 1.16, P<0.05
24mo mortality RR 1.29 (NS)
Zambia10
292
197
Infants tested several times; mothers not re-tested
Not stated 9mo-3yr mortality
HR 3.2 (95%CI, 0.7-14.0), P=0.13
Small number of HEU and HIV-unexposed infants Not followed from birth Period of highest morbidity and mortality not captured (birth-6mo) Hazard ratios not adjusted for confounders Mothers not retested – unexposed group possibly contaminated with HEU or HIV-infected infants Feeding modality not stated
Rwanda11
138209
Mothers and infants tested several times
Majority breastfedMedian of 18mo breastfeedingExclusivity not reported
5yr mortality HR 0.4 (95%CI 0.1-1.6), P= 0.20 Small number of HEU and HUU infants Hazard ratios not adjusted for confounders Long follow-up, but without breakdown into different time periods
The Gambia12
HIV-1N=64
HIV-2 N=194
HUU=448
Infants re-tested several times; mothers not re-tested
Not stated
Median 6yr mortality
HIV-1 HR 1.6 (95%CI 0.81-3.3) P=0.18
Small number of HEU infants HIV-1 and HIV-2 exposed uninfected infants included Infants without HIV test classified as unknown Unclear how missing results were treated – possibility that HEU group contaminated with
undiagnosed postnatally infected infants Feeding modality not stated More accurate HIV status when findings conditioned on survival to 4mo or 18mo
HIV-2 HR 1.2 (95%CI 0.70-2.0) P=0.5
Median 6yr mortality conditional on survival to 4mo
HIV-1 HR 2.7 (95%CI 1.3-5.6)
HIV-2 HR 2.0 (95%CI 1.1-3.6)
Median 6yr mortality conditional on survival to 18mo
HIV-1 HR 3.6 (95%CI 1.6-8.1)
HIV-2 HR 2.2 (95%CI 1.1-4.4)
Single dose nevirapine for PMTCT
22
South Africa13
936
1155
Infants tested monthly; mothers not re-tested
Never BF:HIV-infected mothers vs. 1.5% HIV-uninfected mothers
6-8w EBF:HIV infected mothers 81.4% vs. HIV-uninfected 92.9%
3-4mo EBF:HIV-infected mothers 61.8% vs. HIV-uninfected 72.6%
12mo mortality aHR 0.77 (95%CI 0.49-1.21), P=0.253
Large number of HEU and HUU infants HAART available before the end of the study (unclear how many mothers received HAART) Only those with available feeding data were included Very high rates of EBF Mothers not retested – unexposed group possibly contaminated with HEU or HIV-infected infants Data on missing test results unavailable
South Africa14
543218
Infants tested several times; mothers not re-tested
12wk EBF:HEU 54.7% vs. HUU 9.4% 9mo mortality HR 0.7 (95%CI 0.3-1.5)
65% of those born to mothers who died not included in analyses – most at-risk infants possibly excluded
Small number of HUU infants Mothers not retested – unexposed group possibly contaminated with HEU or HIV-infected infants
Single dose nevirapine and 6 months infant zidovudine for PMTCT
Botswana15
534
137
Infants tested several times; mothers not tested
Median BF duration:HIV-infected mothers 5.8mo vs. HIV-uninfected mothers 9.0mo
5mo EBF:HIV-infected mothers 17.5% vs. HIV uninfected mothers 9.5%
6mo mortality HEU 3.6% vs. HUU 0.8%, P=0.01
HIV-infected mothers breastfed for less time, but significantly more were exclusively breastfeeding at 5 months
Small number of HUU infants HAART available before the end of the study (unclear how many mothers received HAART) Mothers not retested – unexposed group possibly contaminated with HEU or HIV-infected infants Infants lost to follow-up censored at last HIV negative test/last study visit
24mo mortality HEU 6.7% vs. HUU 1.6%, P=0.002
Co-trimoxazole prophylaxis (HEU infants only) and single dose nevirapine for PMTCT
Malawi/Tanzania/Zambia16
1573
131
Infants tested several times; mothers not re-tested
Possibility of HEU group including postnatally infected inftants
Not stated 12mo mortality HEU 7.2% vs. HUU 4.8% (no statistical test performed)
Large number of HEU infants Infants lost to follow-up/died without recent testing not included Breastfeeding not stated Small number of HUU infants No statistical comparisons undertaken Mothers not retested – unexposed group possibly contaminated with HEU or HIV-infected infants Possibility of HEU group including postnatally infected inftants
Co-trimoxazole prophylaxis (HEU infants only) and single nevirapine and 4 weeks zidovudine for PMTCTMozambique17
158160
Not clear if PN included in analysis
Similar feeding until 6moHUU breastfed for longer100% of HUU breastfed to 12mo
12mo mortality OR 3.74 (95%CI 0.41-34.26), P= 0.195
Not primary trial outcome Small number of HEU and HUU infants
Co-trimoxazole prophylaxis (HEU infants only)Uganda18
186
389
Infants tested at several time points; mothers not re-tested
Breastfeeding at 6mo:84.4% vs. 99.7%, P<0.001
Breastfeeding at 12mo:28.7% vs. 98.9%, P<0.0001
Breastfeeding at 24mo:0% vs. 24%, P<0.0001
24mo mortality13.7 (95%CI 1.12-167.3), P=0.04
Dedicated study clinic Recruited from 4mo of age; period of highest morbidity and mortality not captured (birth-4mo) Adjusted for age, malaria prophylaxis, breastfeeding and wealth index
HEU=HIV-exposed uninfected; HUU=HIV unexposed uninfected; PN=postnatally HIV infected; N=number included; ART=anti-retroviral therapy; HAART=highly-active anti-retroviral therapy; PMTCT=prevention of mother-to-child transmission; wks=weeks; mo=months; yrs=years; (a)HR=(adjusted) hazard ratio; RR=relative risk; NS=not statistically significant.
23
Table 2: Comparison of vaccination responses between HEU and HIV-unexposed infants
Country HEU infants (n)
HUU infants (n)
Main findings (HIV-exposed vs. HIV-unexposed) Summary
Diphtheria
South Africa76 120 114 No difference in antibody concentration or proportion of infants protected Brazil149 19 112 No difference in antibody concentration or proportion of infants protected Tetanus
South Africa73 38 55 No difference in antibody concentration South Africa76 120 114 No difference in antibody concentration or proportion of infants protected South Africa81 27 28 No differences in antibody concentration post-primary DTP, but higher concentration post-booster response in HEU infants. No
differences in proportion protected
South Africa82 120 60 No difference in antibody concentration or proportion of infants protected Brazil149 19 112 Lower concentrations of specific antibody in HEU infants, but no difference in seroprotection. Uganda150 Not
stated, approx. 129
Not stated, approx. 1304
Reduced IFN-γ, IL-5 and IL-13 responses to tetanus toxin in HEU infants
Kenya151 8 (3mo)26 (12 mo)
8 (3 mo)17 (12 mo)
No differences in response to TT antigens at 3 months. At 12 months, lower CD4 IL-2 response and dual IL-2 /TNF- response to TT antigens in HEU infants
Pertussis (PT & FHA)
South Africa73 38 55 Higher antibody concentration in HEU infants, higher fold increase pre- to post-vaccination South Africa76 120 114 Higher PT antibody concentration in HEU infants, but similar FHA antibody concentration. Increased proportion of HEU infants with 4-
fold increase in PT antibody concentration, but no difference between HEU and HUU infants for FHA antibody
South Africa81 27 28 Higher antibody concentration in HEU infants post primary and pre-booster vaccines, no difference post-booster. Higher proportion of seropositive HEU infants at 6 months
South Africa82 120 60 Higher antibody concentration in HEU infants at 24 weeks, but no difference at 14 and 52 weeks. Higher proportion of seropositive HEU
infants at 24 weeks
Hib (PRP)Uganda (HEU) & USA (HUU)72
57 14 Higher antibody concentration in HEU infants at 48 weeks, but no difference in avidity South Africa73 38 55 No difference in antibody concentration after 3 vaccine doses at 16 weeks, but higher fold increase pre- to post-vaccination South Africa76 120 114 No difference in antibody concentration or SBA GMT South Africa81 27 28 No difference in vaccine responses South Africa82 120 60 Higher antibody concentration in HEU infants at 14 and 24 weeks, but no difference at 52 weeks. Higher proportion of HEU infants with
protective immunity
Denmark83 19 7 No difference in vaccine responses 24
Pneumococcal capsular polysaccharide
South Africa73 38 55 Higher antibody concentration in HEU infants, higher fold increase pre- to post-vaccination South Africa84 120 114 No differences in GMC for ST4, 9V, 14, 18C, 19F, higher GMC for ST 6B and 23F in HEU infants after 3 doses of PCV. No difference
in seroprotection, except for ST 6B. Similar results in OPA
South Africa152 121 116 No differences in GMC for ST 6B, 9V, 14, 18C, 19F, 23F, higher GMC for ST 4 in HEU infants after 2 doses of PCV. No difference in seroprotection, except for ST 4Similar results for most ST in OPA
Hepatitis B
South Africa76 120 114 Lower antibody concentration in HEU than HUU infants. No difference in seroprotection South Africa81 27 28 No difference in vaccine responses South Africa82 120 60 Lower antibody concentrations in HEU infants at 14 and 52 weeks, no difference at 24 weeks. No differences in proportion protected Brazil149 45 112 Increased proportion of HEU infants with high responses, similar proportion with very low responses. Measles
South Africa81 27 28 No difference in vaccine responses post-primary or post-booster measles vaccine South Africa85 116 112 Post-primary vaccine: Greater vaccine responses; no difference in seroprotection rates
Post-booster vaccine: No difference in vaccine responses; no difference in seroprotection ratesAt 2 years of age: Poorer vaccine responses in HEU infants; fewer HEU infants with seroprotection
Oral polo vaccine
Zambia153 133 397 Lower mean antibody titre in HEU infants, but no difference when breastfeeding adjusted for BCG
South Africa67 46 46 No difference in BCG-specific T-cell proliferation at 6 weeks; higher frequency at 14 weeks in HEU infant; decreased cytokine polyfunctionality in HEU infants
South Africa68 47 62 No difference in BCG-specific T-cell proliferation, intracellular cytokine expression, polyfunctional T cells or secreted cytokines Uganda150 Not
stated, approx. 136
Not stated, approx.1370
No difference in responses to crude culture filtrate proteins of Mycobacterium tuberculosis
Kenya151 16 (3mo)29 (12 mo)
9 (3 mo)17 (12 mo)
No differences in frequency of responders to PPD antigens at either time point. At 3 months, increased frequency of IL-2/TNF- dual positive PPD-specific CD4 T cells in HEU infants. Alterations in memory T cell subsets at 3 months of age in response to PPD stimulation.
South Africa154 94 12 No significant differences in BCG-specific release of IFN-γ, measured by ELISA South Africa155 25 23 No difference in BCG-specific CD4 T cell cytokine response or polyfunctional cells Brazil156 58 38 Delayed BCG responses in HEU infants – by 18.1-26.3mo HEU had similar responses to HUU infants aged 7.0-8.7mo HUU= HIV-unexposed uninfected, GMC=Geometric mean concentration, PT=Pertussis toxin, FHA=filamentous hemagglutinin, PRP=polyribosyl-ribitol phosphate, SBA=serum bactericidal assay, OPV=oral polio vaccine, DTwP=diphtheria, tetanus toxoid, cellular pertussis vaccine, BCG=Bacille Calmette-Guerin, Hib=Haemophilus
25
influenzae type b, HBV=hepatitis B vaccine, ST=serotypes, mo=months better results in HEU infants, poorer results in HEU infants, similar results between HEU and
HUU infants.
Table 3: Fetal and postnatal growth of HEU infants in developing countries before the availability of ARTNS=not significant, OR=odds ratio, LAZ=length for age Z-score, WAZ=weight for age Z-score, WLZ=weight for length Z-score, SGA=small for gestational age, w=weeks, m=months, SD=standard deviation, SE=standard error, IQR=inter-quartile range*Significantly poorer outcome of HEU compared to HIV-unexposed infants**Significantly poorer outcome of HIV-unexposed compared to HEU infants
Country HEU infants (n)
HIV-unexposed comparison group (n)
Follow-up period Main findings (HIV-exposed vs. HIV-unexposed)
Birth weight
Zimbabwe8 3135 9510 Mean birth weight (SD): 2·94kg (0·46) vs. 3·00kg (0·45), p<0·05*;Percentage low birth weight: 15·3% vs. 12·1%, p<0·05*; odds ratio for underweight at birth: 1.12 (95%CI 0.97-1.29)
Malawi91 270 686 Significant difference in mean birth weights*Democratic Republic of
Congo157 190 256 Mean birth weight (SE): 2·95kg (0·35) vs. 3·04kg (0·32)* (P value not stated)Mean z-score at birth (SE): +0.20 (0·07) vs. -0·47 (0·07) (P value/comparison not stated)
StuntingMalawi91 270 686 24 months Lower mean LAZ to 24mo*
Democratic Republic of Congo157 190 256 20 months No difference in mean LAZ scores to 20mo
Kenya158 155 139 18 months Mean LAZ scores: -0·48 vs. -0·19, p<0·05* at 1·5mo only, otherwise similar
Rwanda159 140 207 48 months Lower mean LAZ scores only at 6mo,* not throughout rest of 48mo follow-upZimbabwe90 3135 9510 48 months 6w OR 1·24, (95%CI 1·10-1·40)*, 6mo OR 1·25 (95%CI 1·09-1·42)*, 12mo OR 1·22 (95%CI 1·08-1·38)*, 18mo NS; 24mo NS
Uganda160 200 400 4-6mo (cross-sectional) Adjusted OR for stunting at median age of 5.2mo: 2.23, p=0.005*
UnderweightMalawi91 270 686 24 months Lower mean WAZ to 24mo*
Democratic Republic of Congo157 190 256 20 months No difference in mean WAZ scores to 20mo
Rwanda159 140 207 48 months No difference in mean WAZ scores to 48moZimbabwe90 3135 9510 24 months 6w OR 1·54 (95%CI 1.29-1·83)*, 6mo OR 1·53 (95%CI 1·26-1·84)*, 12mo OR 1·38 (95%CI 1·16-1·65)*, 18mo NS; 24mo NS
Uganda160 200 400 4-6mo (cross-sectional) Adjusted OR for underweight at median age of 5.2mo: 1.73, p=0.09
WastingDemocratic Republic of
Congo157 190 256 20 months No difference in mean WLZ scores to 20mo
Kenya158 155 139 18 months Mean WLZ at 6mo: 0·45 vs. 0·10, p<0·05**Mean WLZ at 18mo: 0·16 vs. -0·73, p<0·05**
Zimbabwe90 3135 9510 24 months 6w OR for wasting 1·60 (95%CI 1·22-2·10)*, 6mo OR 1·39 (95%CI 1·04-1·87)*, 12mo (OR 1·55, 95%CI 1·21-1·99)*, 18mo NS; 24mo NS
Malawi91 270 686 24 months Lower mean WLZ to 24mo*Uganda160
200 400 4-6mo (cross-sectional) Adjusted OR for wasting at median age 5.2mo: 3.29, p=0.02*
26
27
Panel 1: Suggested areas for future research in HEU infantsAssess mortality and growth of HEU infants in the ART era
Clarify deleterious effects of ART exposure Better understand whether poorer outcomes of HEU infants persist in the current era, comparing HEU
infants exposed to ART, with appropriate HIV-unexposed groupsDetermine the causes of infection susceptibility
Discern the relative impacts of immunological abnormalities, maternal caretaking capabilities, exposure to opportunistic infections, and feeding methods
Explore the relationship between inflammation and infection susceptibility/growth of HEU infantsBetter characterise the immune function of HEU infants
Evaluate ontogeny of the innate and adaptive immune system in HEU infants Define functional immune defects in HEU infants using modern immunological techniques Determine the effect of HIV exposure on immune activation beyond infancy and early childhood
Evaluate the mechanisms of immune activation, inflammation, and T-cell abnormalities Explore the contributions of maternal/infant enteropathy, maternal/infant microbial translocation, maternal
CD4 count, exposure to HIV in utero or through breastfeeding, maternal/infant co-infections, maternal/infant malnutrition, and exposure to ART
Assess the impact of immunological abnormalities on mortality/morbidity outcomes of HEU infants Correlate markers of immune dysfunction with clinical outcomes Better understand the time-course of immune defects and interventions that may be beneficial Determine the long-term impact of immune activation on health outcomes
Evaluate the impact of co-trimoxazole Evaluate the impact of co-trimoxazole on immune activation, HIV transmission, growth and health of HEU
infants
Infection prophylaxis and vaccination strategies Explore the role of additional antimicrobial prophylaxis to prevent co-infections, including CMV, TB, PCP Explore the protection provided by antenatal immunisation, neonatal vaccination or accelerated vaccination
schedule to young infants and the potential for modulation of the infant’s own response to vaccination
Identification of novel techniques to reduce the transmission of HIV during breastfeeding Breastfeeding may ameliorate some of the risks associated with HIV exposure, but HIV transmission is still
possible
28
FIGURES
Fig 1: Reduction in perinatally HIV-infected infants with increasing PMTCT coverageThe number of pregnant women living with HIV in low-income and middle-income countries declined slightly between 2005 and 2013, from 1.64 million to 1.45 million (chart plots, Source: http://www.who.int/hiv/data/arvpmtct2014.png.) Over the same period, the proportion of HIV-infected pregnant women receiving effective PMTCT interventions increased from 13% in 2005 to 72% in 2013 (grey shaded areas, Source: http://www.who.int/hiv/data/arvpmtct2014.png), leading to a striking reduction in the number of HIV-infected infants (line plots, Source: UNAIDS Fact Sheet 2015). The number of HIV-exposed uninfected (HEU) infants is therefore increasing.PMTCT=prevention of mother-to-child transmission
2005 2006 2007 2008 2009 2010 2011 20120
200000
400000
600000
800000
1000000
1200000
1400000
1600000
0
100000
200000
300000
400000
500000
13%22%
31%40% 47%
47%56%
62%
Year
Num
ber o
f pre
gnan
t wom
en d
eliv
erin
g w
ith H
IV in
low
- an
d m
iddl
e-in
com
e co
utnr
ies,
with
sha
ded
area
s re
p-re
sent
ing
PM
TCT
cove
rage
Num
ber of new H
IV infections in childre in low
- and m
iddle-income countries
29
References
1. Datta P, Embree JE, Kreiss JK, et al. Mother-to-child transmission of
human immunodeficiency virus type 1: report from the Nairobi Study. J
Infect Dis 1994; 170: 1134–40.
2. Shapiro R, Kitch D, Ogwu A, et al. HIV transmission and 24-month
survival in a randomized trial of HAART to prevent MTCT during
pregnancy and breastfeeding in Botswana. AIDS 2013; 27: 1911–20.
3. Forbes J, Alimenti AM, Singer J, et al. A national review of vertical HIV
transmission. AIDS 2012; 26: 757–63.
4. WHO. Consolidated guidelines on the use of antiretroviral drugs for
treating and preventing HIV infection: recommendations for a public
health approach. Geneva: World Health Organization, 2013.
http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf
(accessed 28th July 2015).
5. UNAIDS. Global plan towards the elimination of new HIV infections
among children by 2015 and keeping their mothers alive. Geneva: Joint
United Nations Programme on HIV/AIDS (UNAIDS), 2011.
http://www.unaids.org/sites/default/files/media_asset/20110609_JC2137_
Global-Plan-Elimination-HIV-Children_en_1.pdf (accessed 28th July
2015).
6. Embree JE, Datta P, Stackiw W, et al. Increased risk of early measles in
infants of human immunodeficiency virus type 1-seropositive mothers. J
Infect Dis 1992; 165: 262–7.
30
7. Thea DM, St Louis ME, Atido U, et al. A prospective study of diarrhea
and HIV-1 infection among 429 Zairian infants. N Engl J Med 1993; 329:
1696–702.
8. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to
maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007;
26: 519–26.
9. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIV-
infected and uninfected children of HIV-infected and uninfected mothers
in rural Uganda. J Acquir Immune Defic Syndr 2006; 41: 504–8.
10. Sutcliffe CG, Scott S, Mugala N, et al. Survival from 9 months of age
among HIV-infected and uninfected Zambian children prior to the
availability of antiretroviral therapy. Clin Infect Dis 2008; 47: 837–44.
11. Spira R, Lepage, P, Msellati, P, et al. Natural history of human
immunodeficiency virus type 1 infection in children: a five-year
prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study
Group. Pediatrics 1999; 104: e56.
12. Schim van der Loeff M, Hansmann A, Awasana AA, et al. Survival of
HIV-1 and HIV-2 perinatally infected children in The Gambia. AIDS
2003; 17: 2289–94.
13. Rollins N, Ndirangu J, Bland R, Coutsoudis A, Coovadia H, Newell M.
Exclusive breastfeeding, diarrhoeal morbidity and all-cause mortality in
infants of HIV-infected and HIV uninfected mothers: an intervention
cohort study in KwaZulu natal, South Africa. PloS One 2013; 8: e81307.
31
14. Chopra M, Doherty T, Goga A, Jackson D, Persson LA. Survival of
infants in the context of prevention of mother to child HIV transmission in
South Africa. Acta Paediatr 2010; 99: 694–8.
15. Shapiro RL, Lockman S, Kim S, et al. Infant morbidity, mortality, and
breast milk immunologic profiles among breast-feeding HIV-infected and
HIV-uninfected women in Botswana. J Infect Dis 2007; 196: 562–9.
16. Chilongozi D, Wang L, Brown L, et al. Morbidity and Mortality Among a
Cohort of Human Immunodeficiency Virus Type 1-Infected and
Uninfected Pregnant Women and Their Infants From Malawi, Zambia, and
Tanzania. Pediatr Infect Dis J 2008; 27: 808–14.
17. Moraleda C, de Deus N, Serna-Bolea C, et al. Impact of HIV exposure on
health outcomes in HIV-negative infants born to HIV-positive mothers in
Sub-Saharan Africa. J Acquir Immune Defic Syndr 2014; 65: 182–9.
18. Marquez C, Okiring J, Chamie G, et al. Increased morbidity in early
childhood among HIV-exposed uninfected children in acill is associated
with breastfeeding duration. J Trop Pediatr 2014; 60: 434–41.
19. Koyanagi A, Humphrey JH, Ntozini R, et al. Morbidity among human
immunodeficiency virus-exposed but uninfected, human
immunodeficiency virus-infected, and human immunodeficiency virus-
unexposed infants in Zimbabwe before availability of highly active
antiretroviral therapy. Pediatr Infect Dis J 2011; 30: 45–51.
20. Landes M, van Lettow M, Chan AK, Mayuni I, Schouten EJ, Bedell RA.
Mortality and health outcomes of HIV-exposed and unexposed children in
a PMTCT cohort in Malawi. PloS One 2012; 7: e47337.
32
21. Slogrove A, Reikie B, Naidoo S, et al. HIV-exposed uninfected infants are
at increased risk for severe infections in the first year of life. J Trop
Pediatr 2012; 58: 505–8.
22. Mussi-Pinhata MM, Freimanis L, Yamamoto AY, et al. Infectious disease
morbidity among young HIV-1-exposed but uninfected infants in Latin
American and Caribbean countries: the National Institute of Child Health
and Human Development International Site Development Initiative
Perinatal Study. Pediatrics 2007; 119: e694–704.
23. Izadnegahdar R, Fox MP, Jeena P, Qazi SA, Thea DM. Revisiting
pneumonia and exposure status in infants born to HIV-infected mothers.
Pediatr Infect Dis J 2014; 33: 70–2.
24. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial
disease, and maternal HIV status on treatment response and cause of
severe pneumonia in South African children: a prospective descriptive
study. Lancet 2007; 369: 1440–51.
25. Slogrove AL, Cotton MF, Esser MM. Severe infections in HIV-exposed
uninfected infants: clinical evidence of immunodeficiency. J Trop Pediatr
2010; 56: 75–81.
26. Kelly MS, Wirth KE, Steenhoff AP, et al. Treatment failures and excess
mortality among HIV-exposed, uninfected children with pneumonia. J
Pediatric Infect Dis Soc 2015; 4: e117–26.
27. Karpelowsky J, Millar A, van der Graaf N, van Bogerijen G, Zar H.
Outcome of HIV-exposed uninfected children undergoing surgery. BMC
Pediatrics 2011; 11: 69.
33
28. von Mollendorf C, Cohen C, de Gouveia L, et al. Risk Factors for Invasive
Pneumococcal Disease among Children less Than 5 Years of Age in a
High HIV-Prevalence Setting, South Africa, 2010 to 2012. Pediatr Infect
Dis J 2015; 34: 27–34.
29. von Mollendorf CA, Tempia S, Meiring S, et al. Increased risk and
mortality of invasive pneumococcal disease in HIV‐exposed‐uninfected
infants <1 year of age in South Africa, 2009‐2013. Clin Infect Dis 2015;
60: 1346–56.
30. Zash R, Shapiro, RL, Leidner, J, et al. The aetiology of diarrhoea,
pneumonia and respiratory colonization of HIV-exposed infants
randomized to breast- or formula-feeding. Paediatr Int Child Health 2015:
[Epub ahead of print].
31. Hsiao N, Zampoli M, Morrow B, Zar HJ, Hardie D. Cytomegalovirus
viraemia in HIV exposed and infected infants: prevalence and clinical
utility for diagnosing CMV pneumonia. J Clin Virol 2013; 58: 74–8.
32. Heresi GP, Caceres E, Atkins JT, Reuben J, Doyle M. Pneumocystis
carinii pneumonia in infants who were exposed to human
immunodeficiency virus but were not infected: an exception to the AIDS
surveillance case definition. Clin Infect Dis 1997; 25: 739–40.
33. Jeena P, Bobat B, Thula SA, Adhikari M. Children with Pneumocystis
jiroveci pneumonia and acute hypoxaemic respiratory failure admitted to a
PICU, Durban, South Africa. Arch Dis Child 2008; 93: 545.
34. Morrow B, Hsaio NY, Zampoli M, Whitelaw A, Zar, HJ. Pneumocystis
pneumonia in South African children with and without human
34
immunodeficiency virus infection in the era of highly active antiretroviral
therapy. Pediatr Infect Dis J 2010; 29: 535–9.
35. Morrow B, Samuel CM, Zampoli M, Whitelaw A, Zar HJ. Pneumocystis
pneumonia in South African children diagnosed by molecular methods.
BMC Res Notes 2014; 7: 26.
36. Paul ME, Chantry CJ, Read JS, et al. Morbidity and mortality during the
first two years of life among uninfected children born to human
immunodeficiency virus type 1–infected women: the women and infants
transmission study. Pediatr Infect Dis J 2005; 24: 46–56.
37. Bekker A, Preez K, Schaaf H, Cotton M, Hesseling A. High tuberculosis
exposure among neonates in a high tuberculosis and human
immunodeficiency virus burden setting. Int J Tuberc Lung Dis 2012; 16:
1040–6.
38. Carina M, Chamie, G, Achan, J, et al. Tuberculosis Infection in Early
Childhood in Uganda and the Influence of HIV Exposure. Conference on
Retroviruses and Opportunistic Infections: Boston, Massachusetts, 2014.
39. Taron-Brocard C, Le Chenadec J, Faye A, et al. Increased risk of serious
bacterial infections due to maternal immunosuppression in HIV-exposed
uninfected infants in a European country. Clin Infect Dis 2014; 59: 1332–
45.
40. Epalza C, Goetghebuer T, Hainaut M, et al. High incidence of invasive
group B streptococcal infections in HIV-exposed uninfected infants.
Pediatrics 2010; 126: e631–8.
35
41. Adler C, Haelterman E, Barlow P, Marchant A, Levy J, Goetghebuer T.
Severe Infections in HIV-Exposed Uninfected Infants Born in a European
Country. PLoS One 2015; 10: e0135375.
42. Larsen E, Lunding S, Helleberg M, et al. Hospitalizations Among
Uninfected Children Exposed or Unexposed to HIV – A Nationwide
Cohort Study. Conference on Retroviruses and Opportunistic Infections:
Seattle, Washington, 2015.
43. McNally L, Jeena PM, Lalloo U, et al. Probable mother to infant
transmission of Pneumocystis jiroveci from an HIV-infected woman to her
HIV-uninfected infant. AIDS 2005; 19: 1548–9.
44. Kuhn L, Kasonde P, Sinkala M, et al. Does severity of HIV disease in
HIV-infected mothers affect mortality and morbidity among their
uninfected infants? Clin Infect Dis 2005; 41: 1654–61.
45. Fox M, Brooks DR, Kuhn L, et al. Role of breastfeeding cessation in
mediating the relationship between maternal HIV disease stage and
increased child mortality among HIV-exposed uninfected children. Int J
Epidemiol 2009; 38: 569–76.
46. Gray K, Kafulafula, G, Matemba, M, Kamdolozi, M, Membe, G, French,
N. Group B Streptococcus and HIV infection in pregnant women, Malawi,
2008–2010. Emerg Infect Dis 2011; 17: 1932–5.
47. Cutland C, Schrag SJ, Zell ER, et al. Maternal HIV infection and vertical
transmission of pathogenic bacteria. Pediatrics 2012; 130: e581–90.
48. Chatterjee A, Bosch RJ, Hunter DJ, Fataki MR, Msamanga GI, Fawzi
WW. Maternal disease stage and child undernutrition in relation to
36
mortality among children born to HIV-infected women in Tanzania. J
Acquir Immune Defic Syndr 2007; 46: 599–606.
49. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated
with weaning persist into the second year of life among uninfected
children born to HIV-infected mothers. Clin Infect Dis 2010; 50: 437–44.
50. Newell M, Coovadia, H, Cortina-Borja, M, et al. Mortality of infected and
uninfected infants born to HIV infected mothers in Africa: a pooled
analysis. Lancet 2004; 364: 1236–43.
51. Slyker JA, Patterson J, Ambler G, et al. Correlates and outcomes of
preterm birth, low birth weight, and small for gestational age in HIV-
exposed uninfected infants. BMC Pregnancy Childbirth 2014; 14: 7.
52. Mussi-Pinhata M, Motta F, Freimanis-Hance L, et al. Lower respiratory
tract infections among human immunodeficiency virus-exposed,
uninfected infants. Int J Infect Dis 2010; 14: e176–82.
53. Mwiru R, Spiegelman D, Hertzmark E, et al. Nutritional predictors of
acute respiratory infections among children born to HIV-infected women
in Tanzania. J Trop Pediatr 2013; 59: 203–8.
54. Afran L, Garcia Knight M, Nduati E, Urban B, Heyderman R, Rowland-
Jones S. HIV-exposed uninfected children: a growing population with a
vulnerable immune system? Clin Exp Immunol 2014; 176: 11–22.
55. Klatt N, Chomont N, Douek DC, Deeks SG. Immune activation and HIV
persistence: implications for curative approaches to HIV infection.
Immunol Rev 2013; 254: 326–42.
37
56. Brenchley J, Price D, Schacker T, et al. Microbial translocation is a cause
of systemic immune activation in chronic HIV infection. Nat Med 2006;
12: 1365–71.
57. Prendergast A, Chasekwa B, Rukobo S, et al. Intestinal damage and
immune activation in HIV-exposed and HIV-infected Zimbabwean infants.
2015 (in press).
58. Bunders M, van Hamme JL, Jansen MH, Boer K, Kootstra NA, Kuijpers
TW. Fetal exposure to HIV-1 alters chemokine receptor expression by
CD4+T cells and increases susceptibility to HIV-1. Sci Rep 2014; 4: 6690.
59. Reikie B, Adams R, Leligdowicz A, et al. Altered innate immune
development in HIV-exposed uninfected infants. J Acquir Immune Defic
Syndr 2014; 66: 245–55.
60. Velilla P, Montoya C, Hoyos A, Moreno M, Chougnet C, Rugeles M.
Effect of intrauterine HIV-1 exposure on the frequency and function of
uninfected newborns’ dendritic cells. Clin Immunol 2008; 126: 243–50.
61. Slyker J, Lohman-Payne B, John-Stewart GC. The impact of HIV-1
infection and exposure on natural killer (NK) cell phenotype in Kenyan
infants during the first year of life. Front Immunol 2012; 3: 399.
62. Miles D, Gadama L, Gumbi A, Nyalo F, Makanani B, Heyderman RS.
Human immunodeficiency virus (HIV) infection during pregnancy induces
CD4 T-cell differentiation and modulates responses to Bacille Calmette-
Guérin (BCG) vaccine in HIV-uninfected infants. Immunology 2010; 129:
446–54.
63. Rich K, Siegel J, Jennings C, Rydman R, Landay A. Function and
phenotype of immature CD4+ lymphocytes in healthy infants and early
38
lymphocyte activation in uninfected infants of human immunodeficiency
virus-infected mothers. Clin Diagn Lab Immunol 1997; 4: 358–61.
64. Ono E, Nunes dos Santos A, de Menezes Succi R, et al. Imbalance of
naive and memory T lymphocytes with sustained high cellular activation
during the first year of life from uninfected children born to HIV-1-
infected mothers on HAART. Braz J Med Biol Res 2008; 41: 700–8.
65. Clerici M, Saresella M, Colombo F, et al. T-lymphocyte maturation
abnormalities in uninfected newborns and children with vertical exposure
to HIV. Blood 2000; 96: 3866–71.
66. Romano M, Buffolano W, Bisogni R, et al. Increased CD154 expression in
uninfected infants born to HIV-positive mothers exposed to antiretroviral
prophylaxis. Viral Immunology 2006; 19: 363–72.
67. Kidzeru E, Hesseling A, Passmore J-A, et al. In-utero exposure to maternal
HIV infection alters T-cell immune responses to vaccination in HIV-
uninfected infants. AIDS 2014; 28: 1421–30.
68. Jones C, Hesseling, AC, Tena-Coki, NG, et al. The impact of HIV
exposure and maternal Mycobacterium tuberculosis infection on infant
immune responses to bacille Calmette-Guérin vaccination. AIDS 2015; 29:
155–65.
69. Economides A, Schmid I, Anisman-Posner D, Plaeger S, Bryson Y,
Uittenbogaart C. Apoptosis in cord blood T lymphocytes from infants of
human immunodeficiency virus-infected mothers. Clin Diagn Lab
Immunol 1998; 5: 230–4.
39
70. Nielsen S, Jeppesen D, Kolte L, et al. Impaired progenitor cell function in
HIV-negative infants of HIV-positive mothers results in decreased thymic
output and low CD4 counts. Blood 2001; 98: 398–404.
71. Liu A, Lohman-Payne B, Chung MH, et al. Maternal plasma and
breastmilk viral loads are associated with HIV-1-specific cellular immune
responses among HIV-1-exposed, uninfected infants in Kenya. Clin Exp
Immunol 2015; 180: 509–19.
72. Gaensbauer J, Rakhola JT, Onyango-Makumbi C, et al. Impaired
Haemophilus acillia type b transplacental antibody transmission and
declining antibody avidity through the first year of life represent potential
vulnerabilities for HIV-exposed but –uninfected infants. Clin Vaccine
Immunol 2014; 21: 1661–7.
73. Jones C, Naidoo S, De Beer C, Esser M, Kampmann B, Hesseling A.
Maternal HIV infection and antibody responses against vaccine-
preventable diseases in uninfected infants. JAMA 2011; 305: 576–84.
74. Jones C, Pollock L, Barnett S, Battersby A, Kampmann B. Specific
antibodies against vaccine-preventable infections: A mother-infant cohort
study. BMJ Open 2013; 3: e002473.
75. Madhi S, Izu A, Violari A, et al. Immunogenicity following the first and
second doses of 7–valent pneumococcal conjugate vaccine in HIV-infected
and –uninfected infants. Vaccine 2013; 31: 777–83.
76. Simani O, Izu, A, Violari, A, et al. Effect of HIV-1 exposure and
antiretroviral treatment strategies in HIV-infected children on
immunogenicity of vaccines during infancy. AIDS 2014; 28: 531–41.
40
77. Cumberland P, Shulman CE, Maple PA, et al. Maternal HIV infection and
placental malaria reduce transplacental antibody transfer and tetanus
antibody levels in newborns in Kenya. J Infect Dis 2007; 196: 550–7.
78. de Moraes-Pinto M, Almeida AC, Kenj G, et al. Placental transfer and
maternally acquired neonatal IgG immunity in human immunodeficiency
virus infection. J Infect Dis 1996; 173: 1077–84.
79. de Moraes-Pinto M, Verhoeff F, Chimsuku L, et al. Placental antibody
transfer: influence of maternal HIV infection and placental malaria. Arch
Dis Child Fetal Neonatal Ed 1998; 79: F202–5.
80. Le Doare K, Allen L, Kampmann B, et al. Anti-group B Streptococcus
antibody in infants born to mothers with human immunodeficiency virus
(HIV) infection. Vaccine 2015; 33: 621–7.
81. Reikie B, Naidoo, S, Ruck, CE, et al. Antibody responses to vaccination
among South African HIV-exposed and unexposed uninfected infants
during the first 2 years of life. Clin Vaccine Immunol 2013; 20: 33–8.
82. Hesseling AC, Jones CE, Blakney AK, et al. Delayed BCG immunization
does not affect antibody responses to EPI vaccines in HIV-exposed South
African infants. In press.
83. Kolte L, Rosenfeldt V, Vang L, et al. Reduced thymic size but no evidence
of impaired thymic function in uninfected children born to human
immunodeficiency virus-infected mothers. Pediatr Infect Dis J 2011; 30:
325–30.
84. Madhi S, Adrian P, Cotton MF, et al. Effect of HIV infection status and
anti-retroviral treatment on quantitative and qualitative antibody responses
41
to pneumococcal conjugate vaccine in infants. J Infect Dis 2010; 202:
355–61.
85. Simani O, Adrian PV, Violari A, et al. Effect of in-utero HIV exposure
and antiretroviral treatment strategies on measles susceptibility and
immunogenicity of measles vaccine. AIDS 2013; 27: 1583–91.
86. Siberry G, Patel K, Bellini WJ, et al. Immunity to Measles, Mumps, and
Rubella in US Children With Perinatal HIV Infection or Perinatal HIV
Exposure Without Infection. Clin Infect Dis 2015: [Epub ahead of print].
87. Kim D, Huey D, Oglesbee M, Niewiesk S. Insights into the regulatory
mechanism controlling the inhibition of vaccine-induced seroconversion
by maternal antibodies. Blood 2011; 117: 6143–51.
88. Wei R, Msamanga GI, Spiegelman D, et al. Association between low birth
weight and infant mortality in children born to human immunodeficiency
virus 1–infected mothers in Tanzania. Pediatr Infect Dis J 2004; 23: 530–
5.
89. Kourtis A, Wiener J, Kayira D, et al. Health outcomes of HIV-exposed
uninfected African infants. AIDS 2013; 27: 749–59.
90. Omoni AO, Ntozini R, Evans C, et al. Child growth according to maternal
and child HIV status in Zimbabwe. Unpublished.
91. Henderson RA, Miotti PG, Saavedra JM, et al. Longitudinal growth during
the first 2 years of life in children born to HIV-infected mothers in
Malawi, Africa. Pediatr AIDS HIV Infect 1996; 7: 91–7.
92. McGrath CJ, Nduati R, Richardson BA, et al. The prevalence of stunting is
high in HIV-1-exposed uninfected infants in Kenya. J Nutr 2012; 142:
757–63.
42
93. Venkatesh KK, Lurie MN, Triche EW, et al. Growth of infants born to
HIV-infected women in South Africa according to maternal and infant
characteristics. Trop Med Int Health 2010; 15: 1364–74.
94. Patel D, Bland R, Coovadia H, Rollins N, Coutsoudis A, Newell ML.
Breastfeeding, HIV status and weights in South African children: a
comparison of HIV-exposed and unexposed children. AIDS. 2010; 24:
437–45.
95. Arpadi S, Fawzy A, Aldrovandi GM, et al. Growth faltering due to
breastfeeding cessation in uninfected children born to HIV-infected
mothers in Zambia. Am J Clin Nutr 2009; 90: 344–53.
96. Ross A RG, Mok J, Gilkison S, Hamilton B, Johnstone FD. Maternal HIV
infection, drug use, and growth of uninfected children in their first 3 years.
Arch Dis Child 1995; 73: 490–5.
97. Agostoni C, Zuccotti GV, Giovannini M, et al. Growth in the first two
years of uninfected children born to HIV-1 seropositive mothers. Arch Dis
Child 1998; 79: 175–8.
98. Neri D, Somarriba G, Schaefer N, et al. Growth and body composition of
uninfected children exposed to human immunodeficiency virus:
Comparison with a contemporary cohort and United States national
standards. Journal of Pediatrics 2013; 163: 249–254.
99. Le Doaré K, Bland, R, Newell, ML. Neurodevelopment in children born to
HIV-infected mothers by infection and treatment status. Pediatrics 2012;
130: e1326–44.
100. Gómez C, Archila ME, Rugeles C, Carrizosa J, Rugeles MT, Cornejo JW.
A prospective study of neurodevelopment of uninfected children born to
43
human immunodeficiency virus type 1 positive mothers. Rev Neurol 2009;
48: 287–91.
101. Nicholson L, Chisenga, M, Siame, J, Kasonka, L, Filteau, S. Growth and
health outcomes at school age in HIV-exposed, uninfected Zambian
children: follow-up of two cohorts studied in infancy. BMC Pediatr 2015 ;
15: 66.
102. Kandawasvika GQ, Kuona P, Chandiwana P, et al. The burden and
predictors of cognitive impairment among 6- to 8-year-old children
infected and uninfected with HIV from Harare, Zimbabwe: a cross-
sectional study. Child Neuropsychol 2015; 21: 106–20.
103. Kerr S, Puthanakit T, Vibol U, et al. Neurodevelopmental outcomes in
HIV-exposed-uninfected children versus those not exposed to HIV. AIDS
Care 2014; 26: 1327–35.
104. Jahanshad N, Couture MC, Prasitsuebsai W, et al. Brain Imaging and
Neurodevelopment in HIV-Uninfected Thai Children Born to HIV-
Infected Mothers. Pediatr Infect Dis J 2015; 34: e211–6.
105. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic
2013. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS),
2013.
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_R
eport_2013_en_1.pdf (accessed 28th July 2015).
106. Quinn T. Global burden of the HIV pandemic. Lancet 1996; 348: 99–106.
107. Ronsmans C, Chowdhury ME, Dasgupta SK, Ahmed A, Koblinsky M.
Effect of parent's death on child survival in rural Bangladesh: a cohort
study. Lancet 2010; 375: 2024–31.
44
108. UNAIDS, UNICEF, USAID. Children on the Brink 2004: A joint report of
new orphan estimates and a framework for action. New York:
UNAIDS/UNICEF/USAID, 2004.
http://www.unicef.org/publications/cob_layout6-013.pdf (accessed 29th
July 2015).
109. Kakkar F, Lamarre V, Ducruet T, et al. Impact of maternal HIV-1 viremia
on lymphocyte subsets among HIV-exposed uninfected infants: protective
mechanism or immunodeficiency. BMC Infectious Diseases 2014; 14:
1471–2334.
110. Gupta RK, Lawn SD, Bekker LG, Caldwell J, Kaplan R, Wood R. Impact
of human immunodeficiency virus and CD4 count on tuberculosis
diagnosis: analysis of city-wide data from Cape Town, South Africa. Int J
Tuberc Lung Dis 2013; 17: 1014–22.
111. Slyker JA, Rowland-Jones SL, Dong T, et al. Acute cytomegalovirus
infection is associated with increased frequencies of activated and
apoptosis-vulnerable T cells in HIV-1-infected infants. J Virol 2012; 86:
11373–9.
112. Schramm D, Kuhn L, Gray G, Tiemessen C. In vivo effects of HIV-1
exposure in the presence and absence of single-dose nevirapine on cellular
plasma activation markers of infants born to HIV-1-seropositive mothers. J
Acquir Immune Defic Syndr 2006; 42: 545–53.
113. Nazli A, Chan O, Dobson-Belaire WN, et al. Exposure to HIV-1 directly
impairs mucosal epithelial barrier integrity allowing microbial
translocation. PloS Pathog 2010; 6: e1000852.
45
114. Townsend C, Tookey PA, Newell ML, Cortina-Borja M. Antiretroviral
therapy in pregnancy: balancing the risk of preterm delivery with
prevention of mother-to-child HIV transmission. Antivir Ther 2010; 15:
775–83.
115. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction
in HIV-1-exposed but uninfected infants: clinical screening in a large
prospective cohort. AIDS 2003; 17: 1769–85.
116. Sibiude J, Mandelbrot L, Blanche S, et al. Association between prenatal
exposure to antiretroviral therapy and birth defects: an analysis of the
ANRS CO1/CO11 French Perinatal Cohort Study. PloS Med 2014; 11:
e1001635.
117. Sibiude J, Le Chenadec J, Bonnet D, et al. In Utero Exposure to
Zidovudine and Heart Anomalies in the ANRS French Perinatal Cohort
and the Nested PRIMEVA Randomized Trial. Clin Infect Dis 2015; 61:
270–80.
118. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child
transmission of HIV: is there any cause for concern? Drug Saf 2007; 30:
203–13.
119. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. Safety
of tenofovir during pregnancy for the mother and fetus: a systematic
review. Clin Infect Dis 2013; 57: 1773–81.
120. Powis KM, Smeaton L, Hughes MD, et al. In-utero triple antiretroviral
exposure associated with decreased growth among HIV-exposed
uninfected infants in Botswana. AIDS 2016; 30: 211–20.
46
121. Mermin J, Were, W, Ekwaru, JP, et al. Mortality in HIV-infected Ugandan
adults receiving antiretroviral treatment and survival of their HIV-
uninfected children: a prospective cohort study. Lancet 2008; 371: 752–9.
122. WHO. Guidelines on co-trimoxazole prophylaxis for HIV-related
infections among children, adolescents and adults: recommendations for a
public health approach. Geneva: World Health Organization, 2006.
http://www.who.int/hiv/pub/guidelines/ctxguidelines.pdf?ua=1 (accessed
29th July 2015).
123. Ford N, Shubber Z, Jao J, Abrams EJ, Frigati L, Mofenson L. Safety of
cotrimoxazole in pregnancy: A systematic review and meta-analysis. J
Acquir Immune Defic Syndr 2014; 66: 512–21.
124. Dryden-Peterson S, Jayeoba O, Hughes MD, et al. Cotrimoxazole
prophylaxis and risk of severe anemia or severe neutropenia in HAART-
exposed, HIV-uninfected infants. PloS One 2013; 8: e74171.
125. Dow A, Kayira, D, Hudgens, M, et al. Effects of cotrimoxazole
prophylactic treatment on adverse health outcomes among HIV-exposed,
uninfected infants. Pediatr Infect Dis J 2012; 31: 842–7.
126. Davis N, Barnett EJ, Miller WC, et al. Impact of Daily Cotrimoxazole on
Clinical Malaria and Asymptomatic Parasitemias in HIV-Exposed,
Uninfected Infants. Clin Infect Dis 2015; 61: 368–74.
127. Sandison T, Homsy J, Arinaitwe E, et al. Protective efficacy of co-
trimoxazole prophylaxis against malaria in HIV exposed children in rural
Uganda: a randomised clinical trial. BMJ (Clinical Research Ed) 2011;
342: d1617.
47
128. Coutsoudis A, Pillay, K, Spooner, E, Coovadia, HM, Pembrey, L, Newell,
ML. Routinely available cotrimoxazole prophylaxis and occurrence of
respiratory and diarrhoeal morbidity in infants born to HIV-infected
mothers in South Africa. South African Medical Journal 2005; 95: 339–45.
129. Madhi S, Nachman S, Violari A, et al. Effect of primary isoniazid
prophylaxis against tuberculosis in HIV-exposed children. N Eng J Med
2011; 365: 21–31.
130. Groome M, Page, N, Cortese, et al. Effectiveness of monovalent human
rotavirus vaccine against admission to hospital for acute rotavirus
diarrhoea in South African children: a case-control study. Lancet Infect
Dis 2014; 14: 1096–104.
131. Nunes M, Cutland CL, Dighero B, et al. Kinetics of Hemagglutination-
Inhibiting Antibodies Following Maternal Influenza Vaccination Among
Mothers With and Those Without HIV Infection and Their Infants. J Infect
Dis 2015; 212: 1976–87.
132. Baroncelli S, Galluzzo CM, Mancinelli S, et al. Antibodies against
pneumococcal capsular polysaccharide in Malawian HIV-positive mothers
and their HIV-exposed uninfected children. Infect Dis (Lond) 2015: 1–5.
133. Hesseling A, Johnson LF, Jaspan H, et al. Disseminated acilli Calmette-
Guérin disease in HIV-infected South African infants. Bull World Health
Organ 2009; 87: 505–11.
134. Fawzy A, Arpadi S, Kankasa C, et al. Early weaning increases diarrhea
morbidity and mortality among uninfected children born to HIV-infected
mothers in Zambia. J Infect Dis 2011; 203: 1222–30.
48
135. Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and
gastroenteritis-associated mortality with early weaning in HIV-1-
uninfected children born to HIV-infected women in Malawi. J Acquir
Immune Defic Syndr 2010; 53: 6–13.
136. Onyango-Makumbi C, Bagenda D, Mwatha A, et al. Early Weaning of
HIV-Exposed Uninfected Infants and Risk of Serious Gastroenteritis:
Findings from Two Perinatal HIV Prevention Trials in Kampala, Uganda.
J Acquir Immune Defic Syndr 2010; 53: 20–7.
137. Homsy J, Moore D, Barasa A, et al. Breastfeeding, mother-to-child HIV
transmission, and mortality among infants born to HIV-Infected women on
highly active antiretroviral therapy in rural Uganda. J Acquir Immune
Defic Syndr 2010; 53: 28–35.
138. Taha T, Hoover DR, Chen S, et al. Effects of cessation of breastfeeding in
HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis 2011; 53:
388–95.
139. Ásbjörnsdóttir KH, Slyker JA, Maleche-Obimbo E, et al. Breastfeeding Is
Associated with Decreased Risk of Hospitalization among HIV-Exposed,
Uninfected Kenyan Infants. J Hum Lact 2015. [Epub ahead of print]
140. Ásbjörnsdóttir K, Slyker JA, Weiss NS, et al. Breastfeeding is associated
with decreased pneumonia incidence among HIV-exposed, uninfected
Kenyan infants. AIDS 2013; 27: 2809–15.
141. Coutsoudis A, Pillay K, Spooner E, Coovadia HM, Pembrey L, Newell
ML. Morbidity in children born to women infected with human
immunodeficiency virus in South Africa: does mode of feeding matter?
Acta Paediatr 2003; 92: 890–5.
49
142. Bork K, Cournil A, Read JS, et al. Morbidity in relation to feeding mode in
African HIV-exposed, uninfected infants during the first 6 mo of life: the
Kesho Bora study. Am J Clin Nutr 2014; 100: 1559–68.
143. WHO. Guidelines on HIV and infant feeding. Principles and
recommendations for infant feeding in the context of HIV and a summary
of evidence. Geneva: World Health Organisation, 2010.
http://apps.who.int/iris/bitstream/10665/44345/1/9789241599535_eng.pdf
(accessed 23rd December 2015).
144. Pedersen SH, Wilkinson AL, Andreasen A, et al. Longitudinal analysis of
mature breastmilk and serum immune composition among mixed HIV-
status mothers and their infants. Clin Nutr 2015. [Epub ahead of print]
145. Gill C, Mwanakasale V, Fox MP, et al. Effect of presumptive co-
trimoxazole prophylaxis on pneumococcal colonization rates,
seroepidemiology and antibiotic resistance in Zambian infants: a
longitudinal cohort study. Bull World Health Organ 2008; 86: 929–38.
146. Muhangi L, Lule S, Mpairwe H, et al. Maternal HIV infection and other
factors associated with growth outcomes of HIV-uninfected infants in
Entebbe, Uganda. Public Health Nutrition 2013; 16: 1548–57.
147. Rollins N, Mahy M, Becquet R, et al. Estimates of peripartum and
postnatal mother-to-child transmission probabilities of HIV for use in
Spectrum and other population-based models. Sex Transm Infect 2012; 88
(Suppl 2): i44–51.
148. UNICEF. The Double Dividend: Action to improve survival of HIV
‘exposed’ children in the era of eMTT and renewed child survival
campaigns. ICASA 2013, Cape Town: UNICEF, 2013.
50
http://www.unicef.org/aids/files/Action_Framework_Final.pdf (accessed
29th July 2015).
149. Abramczuk BM, Mazzola TN, Moreno YMF, et al. Impaired humoral
response to vaccines among HIV-exposed uninfected infants. Clin Vaccine
Immunol 2011; 18: 1406–9.
150. Elliott AM, Mawa PA, Webb EL, et al. Effects of maternal and infant co-
infections, and of maternal immunisation, on the infant response to BCG
and tetanus immunisation. Vaccine 2010; 29: 247–255.
151. Garcia-Knight MA, Nduati E, Hassan AS, et al. Altered Memory T-Cell
Responses to Bacillus Calmette-Guerin and Tetanus Toxoid Vaccination
and Altered Cytokine Responses to Polyclonal Stimulation in HIV-
Exposed Uninfected Kenyan Infants. PLoS One 2015; 10: e0143043.
152. Madhi S, Izu A, Violari A, et al. Immunogenicity following the first and
second doses of 7–valent pneumococcal conjugate vaccine in HIV-infected
and –uninfected infants. Vaccine 2013; 31: 777–83.
153. Sanz-Ramos M, Manno D, Kapambwe M, et al. Reduced Poliovirus
vaccine neutralising-antibody titres in infants with maternal HIV-exposure.
Vaccine 2013; 31: 2042–9.
154. Van Rie A, Madhi SA, Heera JR, et al. Gamma interferon production in
response to Mycobacterium bovis BCG and Mycobacterium tuberculosis
antigens in infants born to human immunodeficiency virus-infected
mothers. Clin Vaccine Immunol 2006; 13: 246–52.
155. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 infection in infants
severely impairs the immune response induced by Bacille Calmette-Guérin
vaccine. J Infect Dis 2009; 199: 982–90.
51
156. Mazzola TN, da Silva MT, Abramczuk BM, et al. Impaired Bacillus
Calmette-Guérin cellular immune response in HIV-exposed, uninfected
infants. AIDS 2011; 25: 2079–87.
157. Bailey RC, Kamenga MC, Nsuami MJ, Nieburg P, St Louis ME. Growth
of children according to maternal and child HIV, immunological and
disease characteristics: a prospective cohort study in Kinshasa, Democratic
Republic of Congo. Int J Epidemiol 1999; 28: 532–40.
158. Sherry B, Embree JE, Mei Z, et al. Sociodemographic characteristics, care,
feeding practices, and growth of cohorts of children born to HIV-1
seropositive and seronegative mothers in Nairobi, Kenya. Trop Med Int
Health 2000; 5: 678–86.
159. Lepage P, Msellati P, Hitimana DG, et al. Growth of human
immunodeficiency type 1–infected and uninfected children: a prospective
cohort study in Kigali, Rwanda, 1988 to 1993. Pediatr Infect Dis J 1996;
15: 479–85.
160. Osterbauer B, Kapisi J, Bigira V, et al. Factors associated with malaria
parasitaemia, malnutrition, and anaemia among HIV-exposed and
unexposed Ugandan infants: a cross-sectional survey. Malar J 2012; 11:
432.
52